Altus Pharmaceuticals Inc (ALTUQ)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

125 SIDNEY STREET CAMBRIDGE, MA 02139

Altus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of oral and injectable protein therapeutics for gastrointestinal and metabolic disorders. The company's products include ALTU-135, a Phase II completed clinical trial product is an orally-administered enzyme replacement therapy for the treatment of malabsorption due to exocrine pancreatic insufficiency; and ALTU-238, a Phase II completed clinical trial product is a crystallized formulation of human growth hormone (hGH) for the treatment of growth hormone deficiency in adults and hGH-related disorders. Its preclinical stage products comprise ALTU-237 for the treatment of hyperoxalurias and kidney stones; ALTU-236, which is designed to reduce the long-term effects associated with excess levels of phenylalanine; and ALTU-242 that is designed to reduce the long-term effects associated with excess levels of urate. The company has strategic alliance with Cystic Fibrosis Foundation Therapeutics, Inc. for the development of ALTU-135, as well as collaboration agreement with Genentech, Inc. to develop, manufacture, and commercializes ALTU-238; and Dr. Falk Pharma GmbH for commercializing ALTU-135 in Europe, the countries of the former Soviet Union, Israel, and Egypt. Altus Pharmaceuticals was incorporated in 1992.

View SEC Filings from ALTUQ instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ALTUQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALTUQ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PRESIDIO MANAGEMENT GROUP VIII L L C

ROOT JONATHAN D

RUST CHRISTOPHER J

YOUNG PHILIP M

  • 10% Owner
No longer subject to file 2009-09-14 0

PRESIDIO MANAGEMENT GROUP VIII L L C

US VENTURE PARTNERS VIII L P

USVP VIII AFFILIATES FUND L P

USVP ENTREPRENEUR PARTNERS VIII A L P

USVP ENTREPRENEUR PARTNERS VIII B L P

CONNORS TIMOTHY J

FEDERMAN IRWIN

FU WINSTON S

KRAUSZ STEVEN M

LIDDLE DAVID E

  • 10% Owner
No longer subject to file 2009-09-14 0

RICHARD JOHN P

  • Director
0 2009-07-01 0

PENNER HARRY JR

  • Director
0 2009-07-01 0

NAVIA MANUEL

  • Director
0 2009-07-01 0

WYZGA MICHAEL S

  • Director
0 2009-07-01 0

PENDERGAST DAVID D PHD

  • Director
0 2009-07-01 0

WARBURG PINCUS PRIVATE EQUITY VIII L P

WARBURG PINCUS PARTNERS LLC

WARBURG PINCUS LLC

WARBURG PINCUS & CO

  • 10% Owner
No longer subject to file 2009-04-16 0

GEMAYEL GEORGES PRESIDENT & CEO

  • Officer
  • Director
0 2009-02-19 0

GOTWALS PHILIP VP, PROGRAM MANAGEMENT

  • Officer
0 2009-01-27 0

ATTIE KENNETH VP, CLINICAL DEV & MED AFFAIRS

  • Officer
0 2009-01-27 0

PHAIR THOMAS J. SR. DIR, FINANCE & CONTROLLER

  • Officer
0 2009-01-27 0

PORTER JILL VP, PROCESS DEV & ENGINEERING

  • Officer
0 2009-01-27 0

HEN STEWART

  • Director
  • 10% Owner
0 2008-06-12 0

LEFF JONATHAN S

  • Director
  • 10% Owner
0 2008-06-12 0

ROOT JONATHAN D

  • Director
  • 10% Owner
0 2008-06-12 0

BLANK BURKHARD EVP & CHIEF MEDICAL OFFICER

  • Officer
0 2008-05-22 0

LIEBER JONATHAN I SVP, CFO AND TREASURER

  • Officer
0 2008-05-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments